Back<\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_single_image source=”featured_image” img_size=”medium” el_class=”image-padding”][vc_custom_heading source=”post_title” font_container=”tag:h1|text_align:left” el_class=”post-heading”][vc_row_inner][vc_column_inner width=”2\/3″][vc_column_text el_class=”post-text”]Amylonix is developing pharmaceuticals focused on the neuorodegenerative area<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”center” width=”1\/3″][vc_column_text el_class=”colored-text”]INVESTERING<\/strong>
\n2018<\/p>\nWEB<\/strong><\/p>\nSTATUS<\/strong>
\nActive<\/p>\nTAGS<\/strong>
\nBiotech<\/span>, neurodegenerative diseases<\/span>, Pharma<\/span>, [\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"Develops pharmaceuticals focused on the neuorodegenerative area<\/p>\n","protected":false},"author":5,"featured_media":3477,"comment_status":"closed","ping_status":"closed","template":"","dt_portfolio_category":[32],"dt_portfolio_tags":[39,96,94],"class_list":["post-1537","dt_portfolio","type-dt_portfolio","status-publish","has-post-thumbnail","hentry","dt_portfolio_category-life-science-en","dt_portfolio_tags-biotech","dt_portfolio_tags-neurodegenerative-diseases","dt_portfolio_tags-pharma","dt_portfolio_category-32","description-off"],"acf":[],"yoast_head":"\n
Amylonix - KTH Holding AB<\/title>\n\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n\t\n